Technology ID
E-203-2018-0

Stable Human Cell Lines Expressing Flavivirus Virus-Like Particles (VLPs) for Vaccine, Biologics, and Diagnostic Development

Linked ID
TAB-3433
Inventors
Brent Davis (CDC)
Gwong-Jen Chang (CDC)
Lead Inventors
Brent Davis (CDC)
Co-Inventors
Gwong-Jen Chang (CDC)
ICs
CDC
Commercial Applications
  • For use in human and animal vaccine and biologics development against flaviviruses such as dengue virus, yellow fever virus, Zika virus, Japanese encephalitis, West Nile virus, Japanese encephalitis virus, St. Louis encephalitis virus, Powassan virus, and others
  • Improved serological diagnostics for flaviviruses in humans and animals and adaptable to kit format
  • Public health monitoring and surveillance for flaviviruses
  • Quality assurance and quality control for vaccine development
  • Research and development
Competitive Advantages
  • Suitable for use as human and animal vaccines and diagnostic antigens
  • VLP strategy has proven effectiveness in CDC's West Nile virus (WNV) and dengue vaccine development
  • Some of these antigens are being utilized in commercially available FDA-approved diagnostic test kits
  • Stable over time (e.g., some clones for a year) without sign of gene expression deterioration
  • Produced from FDA-approved cell lines
  • Selected without antibiotics and propagated in a serum-free and animal protein-free culture media
  • Partners can directly incorporate the cell lines into a manufacturing pipeline for vaccines, biologics, or diagnostics

Request More Info

Licensing Contact